Flow cytometric (FCM) analysis of DNA content is routinely used in several centres to obtain biological information of prognostic and therapeutic relevance for various human tumour types. In particular, FCM analysis has been extensively used in colorectal cancer to evaluate ploidy (Bauer et al., 1987; Kouri et al., 1990; Quirke et al., 1987; Schutte et al., 1987) . Different frequencies of aneuploid tumours and conflicting information on the prognostic relevance of ploidy have been reported by different studies (Armitage et al., 1990; Jass et al., 1989; Jones et al., 1988; Kokal et al., 1986; Kouri et al., 1990; Quirke et al., 1987) and can be ascribed to technical and biological reasons. One of the most crucial points is the type of material used for FCM analysis. Paraffin-embedded samples can involve interpretative problems owing to the lack of an internal standard and the sometime poor quality of DNA histograms due to a large amount of debris (Cusick et al., 1990; Giaretti et al., 1991; Hedley et al., 1989 ; Kallioniemi et al., 1988) . Different protocols to obtain cell or nuclei suspensions from fresh or frozen specimens had been used, but The mean coefficient of variation of the diploid peak was 5% (range, 3.5-7.8%) in the IRE series and 3.5% (range, 2.7-6.5%) in the INT series. DNA ploidy was defined as DNA index (DI), i.e., as the ratio between the mean channel number of the GO/, peak of tumour cells and that of lymphocytes. Tumours with a DNA index different from 1 were considered to be aneuploid. When two cell populations were present, the highest DNA index was used to define tumour ploidy; when three or more cell populations were present, the DNA index of the largest aneuploid population was chosen as representative of the tumour. Differences in DNA ploidy patterns among the various clinico-pathological subsets were analysed by the chi-square and the Wilcoxon rank-sum tests. The Bonferroni procedure was adopted to test multiple comparisons. Relapse-free survival (RFS) and overall survival (OS) were computed, starting from the date of surgery, by means of the Kaplan-Meier (1958) product-limit method. The log rank test was used to assess differences among subgroups.
The role of ploidy as a prognostic variable (univariate analysis) was evaluated by resorting to a Weibull regression model. In this model each regression coefficient (p) is recognisable as the log of the hazard ratio and it is constant in time. For ploidy the unadjusted hazard ratio and its 95% confidence interval were estimated according to a regression model containing only that variable, by using the putative best prognosis as reference category. (Table III) . DNA ploidy was analysed in relation to site of the primary tumour, Dukes' stage and histological grade (Table IV) . No significant relation was observed between DNA ploidy of the primary tumour and any of the considered variables in either of the case series. However, a higher frequency of aneuploid tumours was observed in Dukes' stage D than in Dukes' stage A tumours (88% vs 33%) in the IRE case series.
The clinical outcome of patients in the two case series was analysed as a function of DNA ploidy. RFS and OS curves for patients with diploid or aneuploid tumours were superimposable in the Milan experience (Figure 1 ). In the IRE experience, slightly better (not statistically significant) RFS and OS were observed during the first 3 years for patients with diploid than for those with aneuploid tumours, but the clinical outcome was similar at 4 years ( Figure 2 ). Similar findings were also reflected by the hazard ratios and their confidence limits for INT and IRE series (Table V) . No additive prognostic information was obtained from a breakdown analysis as a function of various DI values and different percentages of aneuploid cells (data not shown).
Conversely, we observed a significantly better RFS in both IRE (78% vs 53%) and INT (55% vs 27%) series for patients with tumours showing a normal DNA content or only one aneuploid subpopulation than for patients with tumours made up of more than one aneuploid subpopulation. Similarly, OS was significantly better in the former than in the latter group (69% vs 33% and 63% vs 35%, respectively) ( Figure 3) . Hazard ratios and their confidence intervals are also reported in Table V to provide a quantitative measure of the effect of multiploid DNA content on RFS and OS. In both the case series the probability of relapse and death was higher for patients with multiploid tumours than for patients with diploid or aneuploid tumours.
Discussion
Colorectal adenocarcinoma is estimated to have a high incidence and mortality among all cancer diagnoses in both sexes. Attempts to reduce mortality have taken many forms, such as identification of patients at different risk for whom there is the necessity to consider the role and the modality of adjuvant treatments. Numerous studies have verified the clinical utility of stage at diagnosis as the single most important prognostic indicator (Wiggers et al., 1988 Years Years Figure 3 Relapse-free a, b, and overall survival c, d, evaluated on series of primary colorectal cancers from two national cancer institutes (broken line, diploid or aneuploid; solid line, multiploid).
Dukes' stages, the similar patient treatment, and the careful follow-up through periodic clinical and instrumental examinations by both the institutes.
In our multicentric study, DNA ploidy, different DI values, and percentage of aneuploid cells were all unable to identify subgroups of patients with different risks of relapse or death, in agreement with the results reported by Kouri et al. (1990) and Rognum et al. (1987) at a similar 4-year follow-up. Conversely, our data are in disagreement with most reported results of several studies with a longer followup (Armitage et al., 1990; Harlow et al., 1991; Rognum et al., 1991) . Such results appear to indicate that DNA ploidy could be a late indicator of survival, and this hypothesis is supported by the appearance of a prognostic relevance of DNA ploidy at 5 years (Rognum et al., 1991) in the same series of patients in which clinical relevance had not been detected at a shorter follow-up (Rognum et al., 1987) . The long time required for DNA ploidy to exhibit its impact on survival is probably due to the limitation of a prognostic relevance to Dukes' stages A, B and C. Conversely, our results showed, for the first time in colorectal cancer, that multiploidy represents an early and eventually unfavourable prognostic factor.
In any case, in view of the biological heterogeneity of colorectal cancer, further analyses on subgroups of patients defined according to the most important prognostic factors, such as Dukes' stage, site of the primary and type of treatment, could even more accurately identify very high-risk patient groups.
